Skip to content
ClinicalOxygen-boosting hormone for endurance and anemia

Erythropoietin (EPO)

Also indexed as Epoetin alfa, rHuEPO, Recombinant Human Erythropoietin

Erythropoietin (EPO) is a glycoprotein hormone naturally produced primarily by the kidneys that regulates red blood cell production. Recombinant human EPO (rHuEPO) mimics this endogenous hormone to stimulate erythropoiesis in the bone marrow, increasing oxygen-carrying capacity. It is clinically approved for anemia associated with chronic kidney disease, chemotherapy, and certain other conditions, but is also widely misused as a performance-enhancing agent in endurance sports.

Overview

Following subcutaneous injection, EPO is slowly absorbed (Tmax ~12–18 hours), with absolute bioavailability of ~20–40% compared to IV administration. It undergoes receptor-mediated endocytosis and proteolytic degradation. Elimination half-life via subq route is approximately 24 hours. Glycosylation (comprising ~40% of molecular weight) prolongs circulating half-life and protects against proteolytic degradation. Hematocrit and reticulocyte counts typically peak 2–3 weeks after initiation. Endogenous EPO production is suppressed via negative feedback as hemoglobin rises.

Proposed mechanism

EPO binds to specific erythropoietin receptors (EPOR) on erythroid progenitor cells in the bone marrow, activating the JAK2/STAT5 signaling pathway. This activation promotes proliferation, differentiation, and survival of red blood cell precursors, ultimately increasing circulating erythrocyte mass and hemoglobin concentration. The resulting increase in red blood cell count enhances oxygen delivery to tissues, improving aerobic capacity and endurance performance.

What the evidence supports

Randomised controlled trial data in humans exists and supports use in specific contexts.

Graded Clinical

Findings supported by randomised, controlled trials in humans, with pre-registered endpoints and published results.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease (CHOIR trial)

    · NEJM, DOI: 10.1056/NEJMoa065485 · 2006

  2. [2]

    Normalization of Hemoglobin Level in Patients with CKD and Anemia (CREATE trial)

    · NEJM, DOI: 10.1056/NEJMoa062276 · 2006

  3. [3]

    Erythropoiesis-stimulating agents and outcomes in patients with non-dialysis CKD

    · Cochrane Database Syst Rev, PMID 22592691 · 2012

  4. [4]

    Recombinant EPO doping in sport: mechanisms, detection, and clinical risks

    · British Journal of Sports Medicine, PMID 19289441 · 2010

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

Adamax

Anecdotal

Nootropic peptide blend for cognition and mood

Adamax is a research peptide blend reported to combine nootropic and neuroprotective peptide components aimed at enhancing cognitive function, mood stability, and neural recovery. It is marketed primarily for its potential effects on dopaminergic and serotonergic signaling pathways. Evidence is largely limited to preclinical and anecdotal sources, with no published human clinical trials specific to the Adamax formulation.

0 RCT · 0 human · 0 preclinical

cognition

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss